At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 509 enrolled
Drug / intervention
Peficitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs
In Brief
A Phase 3 clinical trial evaluating Peficitinib, Placebo, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 509 participants across 153 sites in 3 countries.
Detailed Summary
The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to DMARDs
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedDec 2014
Primary CompletionJan 2017
Study CompletionNov 2017
TodayJul 2026
First PostedDec 4, 2014
Enrollment StartAug 8, 2014
Primary CompletionJan 23, 2017
Study CompletionNov 22, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.6 years ago
Interventions
Peficitinibdrug
oral
Placebodrug
oral
Etanerceptbiological
subcutaneous injection